Lv32
258 积分 2026-01-19 加入
Uric acid in health and disease: From physiological functions to pathogenic mechanisms
14天前
已完结
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
1个月前
已完结
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study
1个月前
已完结
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial
1个月前
已完结
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
1个月前
已完结
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
1个月前
已完结
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
1个月前
已完结
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
1个月前
已完结
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician
2个月前
已完结
Targeting Janus Kinase (JAK) for Fighting Diseases: The Research ofJAK Inhibitor Drugs
2个月前
已完结
皖公网安备34019202002308
